Publications by authors named "C Zallot"
Article Synopsis
- The study aimed to find the best treatment strategies for perianal Crohn's disease (PCD) by evaluating medical and surgical options over a 20-year period.
- Researchers reviewed the medical records of 200 patients and found that combining TNFα antagonists with immunosuppressants and performing certain surgeries improved the chances of fistula closure.
- They concluded that a combined approach, specifically using medical therapy alongside seton placement and additional surgery within one year, is the most effective management for PCD patients.
Introduction: The objective of this study was to describe the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after stopping for loss of response or intolerance.
Methods: We conducted a prospective multicenter observational cohort study including adult patients with clinically (CD Activity Index >150) and objectively active luminal CD in whom IFX was reintroduced after at least 6 months of discontinuation. The reasons for the initial discontinuation could be a secondary loss of response or IFX intolerance.
Article Synopsis
- Budesonide is the main treatment for microscopic colitis (MC), but frequent relapses and some patients being intolerant lead to the exploration of anti-TNF therapy in those who do not respond to budesonide.
- In a study of 14 budesonide-refractory MC patients treated with anti-TNF agents, 35.7% achieved clinical remission and 64.3% showed improvement in stool frequency after 12 weeks.
- The study concludes that anti-TNF therapy can be effective for about half of patients with MC who fail budesonide, marking a significant finding in the treatment of this condition.
Article Synopsis
- Crohn's disease (CD) affects around 20% of patients with complications such as perianal fistulas, where achieving permanent closure remains difficult for doctors.
- This study aimed to explore how serum adalimumab (ADA) levels relate to the clinical remission of fistulas associated with CD.
- Results showed that higher serum ADA concentrations were linked to successful clinical remission, with 44% of patients achieving it, but no significant difference was found in ADA levels between those with and without healed fistulas.